Boehnke Kevin F, Cox Kasey, Weston Cody, Herberholz Moss, Glynos Nicolas, Kolbman Nicholas, Fields Christopher W, Barron Julie, Kruger Daniel J
Anesthesiology Department, University of Michigan Medical School, Ann Arbor, MI, United States.
Chronic Pain and Fatigue Research Center, University of Michigan Medical School, Ann Arbor, MI, United States.
Front Psychiatry. 2023 Aug 4;14:1224551. doi: 10.3389/fpsyt.2023.1224551. eCollection 2023.
There is substantial public interest in psychedelics as potential treatments for psychiatric conditions. However, most psychedelics are criminalized under federal law in the USA, so it is unclear whether use occurs with clinical support. Our objective was to assess whether naturalistic psychedelic use occurs with clinical support, interactions between those using psychedelics and healthcare providers (psychiatrist, therapist, or primary physicians), and use characteristics.
We conducted an online, anonymous, confidential, cross-sectional survey of adults reporting psychedelic use ( = 1221) through a psychedelics advocacy event and social media between 9/18/2022 and 11/5/2022. We assessed participant disclosure of psychedelic use with their psychiatric care provider (PsyCP) and/or primary care provider (PCP), desire for provider support, access to support, and rate of taking prescribed psychoactive medications alongside psychedelics.
Among participants with such care providers, 22% disclosed psychedelic use to their PCP vs. 58% to their PsyCP. Participants were less confident in PCP vs. PsyCP ability to integrate psychedelics into treatment. Common reasons for nondisclosure included stigma, inadequate provider knowledge, and legal concerns. 23% reported taking psychedelics on the same day as potentially interacting psychiatric medications (e.g., anxiolytics, antidepressants). Despite 81% of participants desiring therapist support during psychedelic experiences, only 15% had received such support.
Our results show that psychedelic use is generally disconnected from primary and psychiatric clinical care. This disconnection may result in safety issues, including inadequate screening for contraindicated conditions, lack of support during emergent adverse events, and drug interactions. Enhanced clinical education and orienting drug policy towards known harms and benefits of psychedelics is needed.
迷幻剂作为精神疾病的潜在治疗方法引起了公众的广泛关注。然而,在美国,大多数迷幻剂在联邦法律下被定为犯罪,因此尚不清楚其使用是否有临床支持。我们的目的是评估自然状态下的迷幻剂使用是否有临床支持、迷幻剂使用者与医疗保健提供者(精神科医生、治疗师或初级医生)之间的互动以及使用特征。
我们通过一个迷幻剂宣传活动和社交媒体,于2022年9月18日至2022年11月5日对1221名报告使用过迷幻剂的成年人进行了一项在线、匿名、保密的横断面调查。我们评估了参与者向其精神科护理提供者(PsyCP)和/或初级护理提供者(PCP)披露迷幻剂使用情况、对提供者支持的渴望、获得支持的情况以及与迷幻剂同时服用处方精神活性药物的比例。
在有此类护理提供者的参与者中,22%向其PCP披露了迷幻剂使用情况,而向PsyCP披露的比例为58%。与PsyCP相比,参与者对PCP将迷幻剂纳入治疗的能力信心较低。不披露的常见原因包括耻辱感、提供者知识不足和法律担忧。23%的人报告在服用可能相互作用的精神药物(如抗焦虑药、抗抑郁药)的同一天服用迷幻剂。尽管81%的参与者在迷幻体验期间渴望得到治疗师的支持,但只有15%的人得到了这种支持。
我们的结果表明,迷幻剂的使用通常与初级和精神科临床护理脱节。这种脱节可能导致安全问题,包括对禁忌情况筛查不足、紧急不良事件期间缺乏支持以及药物相互作用。需要加强临床教育,并使药物政策朝着了解迷幻剂的已知危害和益处的方向发展。